VERAOverviewFundamentalsDividendsTechnicalsRiskCatalystsNewsFinancial DataAIQ Pro
Current stock page

Catalysts

VERA Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Sep 11, 2026

VERA

Catalysts
Vera Therapeutics, Inc.
Healthcare· Biotechnology
AIQ Score
NeutralAIQ Edge 3/10
Low Priority
Relative Laggard
Score data as of Sep 11, 2026
Last price
$35.05
+$1.45 (+4.32%)
Latest market quote
Momentum50
Value—
Quality27
Risk Resilience57
Sentiment53
View financial data

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Nov 4, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 42/100

Momentum 50/100 and sentiment 53/100 before the next covered event.

Recent coverage
5 articles

Updated Sep 11, 2026 · Sentiment 26.32%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 50/100AIQ Edge 3/10 Relative Laggard
Beat rate
25%
2 of 8 reported periods
Average surprise
-12.1%
Across covered historical reports
Latest result
+3.8%
Aug 10, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Aug 10, 2026—-$1.58-$1.52+3.8%$1.28M—
May 7, 2026—-$1.33-$1.69-27.2%$426.03K—
Feb 26, 2026—-$1.34-$1.39-3.7%——
Nov 5, 2025—-$1.20-$1.26-5.0%——
Aug 5, 2025—-$0.82-$1.20-46.3%——
May 6, 2025—-$0.75-$0.81-8.0%——
Feb 26, 2025—-$0.83-$0.72+13.3%——
Nov 7, 2024—-$0.69-$0.85-23.2%——

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
13
Buy
1
Hold
12-month analyst target
$86.75
+147.50% versus current price
Based on 8 analyst observations. Targets are estimates, not predictions.
Low target
$43.00
+22.68% vs latest price
Average target
$86.75
+147.50% vs latest price
High target
$125.00
+256.63% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateNov 4, 2026

Next known earnings or reporting date.

EPS estimate-$1.61

Current analyst expectation for the upcoming report.

Revenue estimate$4.28M

Current analyst expectation for the upcoming report.

Sentiment score53

News pressure around the setup.

Momentum score50

Where event reaction would show up first.

AIQ score42/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
8
Average target
$86.75
Target upside
147.50%
Target range
$43.00 - $125.00
90-day revisions
-49

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
1
Negative
0
manilatimes.net · Sep 4, 2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 61,500 shares of Class A common stock and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

manilatimes.net · Sep 1, 2026

Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences.

gurufocus.com · Aug 31, 2026

AN2 Therapeutics (ANTX) to Present Key Clinical Data at SOHO 2026 Amid Valuation Challenges

On August 31, 2026, AN2 Therapeutics Inc (NASDAQ: ANTX) announced it will present four abstracts at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeti

seekingalpha.com · Aug 17, 2026

Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy (NASDAQ:VERA)

Vera Therapeutics is upgraded to Buy following TRUTAKNA's FDA approval and encouraging eGFR data. Learn more about VERA stock here.

manilatimes.net · Aug 7, 2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 63,011 shares of Class A common stock and restricted stock units (RSUs) underlying 44,987 shares of Class A common stock to Nancy Bowman, M.D., Ph.D., Vera’s new Chief Regulatory Officer, under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan), and on August 4, 2026, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 5,600 shares of Class A common stock and RSUs underlying 2,800 shares of Class A common stock to two (2) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Open full news and sentiment

Related Links

VERA Catalysts FAQ

What are the next catalysts for VERA stock?

VERA's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move VERA stock?

Upcoming events that could move VERA include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could VERA's next earnings report affect the stock?

VERA's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive VERA stock higher?

VERA could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt VERA stock?

VERA could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.